Document Report Card

ID: ALA3217627

Journal: Medchemcomm

Title: Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Authors: Pfefferkorn JA, Guzman-Perez A, Oates PJ, Litchfield J, Aspnes G, Basak A, Benbow J, Berliner MA, Bian J, Choi C, Freeman-Cook K, Corbett JW, Didiuk M, Dunetz JR, Filipski KJ, Hungerford WM, Jones CS, Karki K, Ling A, Li J, Patel L, Perreault C, Risley H, Saenz J, Song W, Tu M, Aiello R, Atkinson K, Barucci N, Beebe D, Bourassa P, Bourbounais F, Brodeur AM, Burbey R, Chen J, D'Aquila T, Derksen DR, Haddish-Berhane N, Huang C, Landro J, Lee Lapworth A, MacDougall M, Perregaux D, Pettersen J, Robertson A, Tan B, Treadway JL, Liu S, Qiu X, Knafels J, Ammirati M, Song X, DaSilva-Jardine P, Liras S, Sweet L, Rolph TP

DOI: 10.1039/C1MD00116G